Detalles de la búsqueda
1.
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
Br J Haematol
; 204(5): 1762-1770, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38500476
2.
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.
Lancet Oncol
; 23(8): 1021-1030, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35835137
3.
Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura.
Blood
; 140(7): 785-789, 2022 08 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35584244
4.
A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
BMC Cancer
; 19(1): 423, 2019 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31060542
5.
Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer.
Carcinogenesis
; 38(1): 2-11, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27838634
6.
Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice.
Immunology
; 152(1): 36-51, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28419443
7.
Emerging links among Chromosome Instability (CIN), cancer, and aging.
Mol Carcinog
; 56(3): 791-803, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27533343
8.
A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.
Br J Haematol
; 175(2): 281-289, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27448091
9.
Genomic profiling is a supplemental diagnostic and therapeutic modality for hairy cell leukemia variant.
Ann Hematol
; 100(6): 1629-1630, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33433650
10.
The TMEFF2 tumor suppressor modulates integrin expression, RhoA activation and migration of prostate cancer cells.
Biochim Biophys Acta
; 1843(6): 1216-24, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24632071
11.
Role of PUF-8/PUF protein in stem cell control, sperm-oocyte decision and cell fate reprogramming.
J Cell Physiol
; 229(10): 1306-11, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24638209
12.
TMEFF2 and SARDH cooperate to modulate one-carbon metabolism and invasion of prostate cancer cells.
Prostate
; 73(14): 1561-75, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23824605
13.
Impact of Race and Age and their Interaction on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 23(5): 379-384, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36813625
14.
Impact of primary organ site of involvement by peripheral T-cell lymphoma not otherwise specified on survival.
Cancer Med
; 12(24): 21770-21778, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38073461
15.
An unbiased seed-based RNAi selection screen identifies small RNAs that inhibit androgen signaling and prostate cancer cell growth.
Mol Ther Nucleic Acids
; 33: 257-272, 2023 Sep 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37554515
16.
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.
Clin Lymphoma Myeloma Leuk
; 23(9): 674-686, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37290996
17.
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
J Clin Oncol
; 41(15): 2815-2826, 2023 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36888930
18.
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
J Clin Oncol
; 41(26): 4236-4246, 2023 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37379495
19.
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
J Clin Oncol
; 41(31): 4893-4904, 2023 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37703506
20.
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Nat Med
; 29(11): 2814-2824, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37857711